RS55258B1 - Korišćenje anti-cd20 antitela tipa ii sa povećanom ćelijskom citotoksičnošću zavisnom od antitela (adcc) u kombinaciji sa ciklofosfamidom, vinkristinom i doksorubicinom za lečenje non-hodgkinovih limfoma - Google Patents

Korišćenje anti-cd20 antitela tipa ii sa povećanom ćelijskom citotoksičnošću zavisnom od antitela (adcc) u kombinaciji sa ciklofosfamidom, vinkristinom i doksorubicinom za lečenje non-hodgkinovih limfoma

Info

Publication number
RS55258B1
RS55258B1 RS20160864A RSP20160864A RS55258B1 RS 55258 B1 RS55258 B1 RS 55258B1 RS 20160864 A RS20160864 A RS 20160864A RS P20160864 A RSP20160864 A RS P20160864A RS 55258 B1 RS55258 B1 RS 55258B1
Authority
RS
Serbia
Prior art keywords
antibody
doxorubicine
adcc
lymphomas
vincristine
Prior art date
Application number
RS20160864A
Other languages
English (en)
Inventor
Charles Dumontet
Thomas Friess
Frank Herting
Christian Klein
Pablo Umana
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40872445&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS55258(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of RS55258B1 publication Critical patent/RS55258B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
RS20160864A 2008-03-25 2009-03-23 Korišćenje anti-cd20 antitela tipa ii sa povećanom ćelijskom citotoksičnošću zavisnom od antitela (adcc) u kombinaciji sa ciklofosfamidom, vinkristinom i doksorubicinom za lečenje non-hodgkinovih limfoma RS55258B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP08005554 2008-03-25
EP08007172 2008-04-11
EP09723808.3A EP2268310B1 (en) 2008-03-25 2009-03-23 Use of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc) in combination with cyclophosphamide, vincristine and doxorubicine for treating non-hodgkin' s lymphomas
PCT/EP2009/002111 WO2009118142A1 (en) 2008-03-25 2009-03-23 Use of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc) in combination with cyclophosphamide, vincristine and doxorubicine for treating non-hodgkin' s lymphomas

Publications (1)

Publication Number Publication Date
RS55258B1 true RS55258B1 (sr) 2017-02-28

Family

ID=40872445

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20160864A RS55258B1 (sr) 2008-03-25 2009-03-23 Korišćenje anti-cd20 antitela tipa ii sa povećanom ćelijskom citotoksičnošću zavisnom od antitela (adcc) u kombinaciji sa ciklofosfamidom, vinkristinom i doksorubicinom za lečenje non-hodgkinovih limfoma

Country Status (31)

Country Link
US (6) US20090246197A1 (sr)
EP (1) EP2268310B1 (sr)
JP (3) JP5547709B2 (sr)
KR (1) KR101280716B1 (sr)
CN (2) CN107198772A (sr)
AR (1) AR072947A1 (sr)
AU (1) AU2009228616B2 (sr)
BR (1) BRPI0909227B8 (sr)
CA (1) CA2716884C (sr)
CL (1) CL2009000713A1 (sr)
CR (1) CR11687A (sr)
CY (1) CY1117984T1 (sr)
DK (1) DK2268310T3 (sr)
ES (1) ES2592312T3 (sr)
HR (1) HRP20161301T1 (sr)
HU (1) HUE028828T2 (sr)
IL (1) IL208018A (sr)
LT (1) LT2268310T (sr)
MA (1) MA32140B1 (sr)
MX (1) MX2010009647A (sr)
MY (1) MY163544A (sr)
NZ (1) NZ587284A (sr)
PE (1) PE20091821A1 (sr)
PL (1) PL2268310T3 (sr)
PT (1) PT2268310T (sr)
RS (1) RS55258B1 (sr)
RU (1) RU2589704C2 (sr)
SI (1) SI2268310T1 (sr)
TW (1) TWI500624B (sr)
WO (1) WO2009118142A1 (sr)
ZA (1) ZA201006190B (sr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9296820B2 (en) 2003-11-05 2016-03-29 Roche Glycart Ag Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
MX2010009647A (es) * 2008-03-25 2010-09-28 Roche Glycart Ag Uso de un anticuerpo anti-cd20 de tipo ii con citotoxicidad celular dependiente del anticuerpo aumentada en combinacion con ciclofosfamida, vincristina y doxorubicina para el tratamiento de linfoma no hodgkiniano.
TW201438738A (zh) 2008-09-16 2014-10-16 Genentech Inc 治療進展型多發性硬化症之方法
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
MX342405B (es) 2010-06-03 2016-09-28 Pharmacyclics Inc El uso de inhibidores de la tirosina quinasa de bruton (btk).
KR20130088170A (ko) * 2010-12-16 2013-08-07 로슈 글리카트 아게 비푸코실화 ｃｄ20 항체와 ｍｄｍ2 저해제와의 조합 치료
US20130302274A1 (en) * 2011-11-25 2013-11-14 Roche Glycart Ag Combination therapy
AU2013293087B2 (en) 2012-07-24 2017-08-31 Pharmacyclics Llc Mutations associated with resistance to inhibitors of Bruton's tyrosine kinase (BTK)
CN105899535A (zh) * 2013-12-17 2016-08-24 豪夫迈·罗氏有限公司 用pd-1轴结合拮抗剂和抗cd20抗体治疗癌症的方法
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) * 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
AU2015315396B2 (en) 2014-09-09 2020-10-08 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
PE20171094A1 (es) 2014-12-04 2017-08-07 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
UA124143C2 (uk) 2015-05-20 2021-07-28 Янссен Байотек, Інк. Антитіла до cd38 для лікування амілоїдозу, викликаного відкладеннями легких ланцюгів імуноглобулінів, і інших cd38-позитивних злоякісних гематологічних новоутворень
CA2990406A1 (en) 2015-06-22 2016-12-29 Janssen Biotech, Inc. Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
SI3370770T1 (sl) 2015-11-03 2021-03-31 Janssen Biotech, Inc. Subkutane formulacije protiteles proti CD38 in njihove uporabe
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
WO2017100714A1 (en) * 2015-12-10 2017-06-15 City Of Hope Cell penetrating cyanine-coupled antibodies
AU2017341047A1 (en) 2016-10-07 2019-05-02 Novartis Ag Chimeric antigen receptors for the treatment of cancer
WO2018106945A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
EP4108183A1 (en) 2017-03-30 2022-12-28 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2019089832A1 (en) 2017-10-31 2019-05-09 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
US20230023414A1 (en) 2018-11-19 2023-01-26 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
KR20220079858A (ko) * 2019-10-04 2022-06-14 추가이 세이야쿠 가부시키가이샤 오비누투주맙 내성 cd20 양성 암의 세포의 증식을 억제하는 제, 및 그에 관련된 의약 조성물, 의약, 제조, 세포의 증식을 억제하는 방법, 치료 방법, ii형 항cd20 항체, 화합물, 그들의 조합, 증강제 및 유도제
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
DK1071700T3 (da) * 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
RU2306952C2 (ru) * 2001-01-31 2007-09-27 Байоджен Айдек Инк. Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами
PL216630B1 (pl) * 2002-10-17 2014-04-30 Genmab As Izolowane ludzkie przeciwciało monoklonalne wiążące ludzki CD20, związane z tym przeciwciałem transfektoma, komórka gospodarza, transgeniczne zwierzę lub roślina, kompozycja, immunokoniugat, cząsteczka bispecyficzna, wektor ekspresyjny, kompozycja farmaceutyczna, zastosowanie medyczne, zestaw oraz przeciwciało antyidiotypowe i jego zastosowanie
ES2347241T3 (es) * 2002-12-16 2010-10-27 Genentech, Inc. Variantes de inmunoglobulina y sus utilizaciones.
US9296820B2 (en) * 2003-11-05 2016-03-29 Roche Glycart Ag Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
DOP2006000029A (es) * 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
EP1891113A2 (en) * 2005-06-02 2008-02-27 AstraZeneca AB Antibodies directed to cd20 and uses thereof
AR055137A1 (es) * 2005-08-26 2007-08-08 Glycart Biotechnology Ag Moleculas de union al antigeno modificadas con actividad de senalizacion celular alterada
CN101821292B (zh) * 2007-09-05 2014-03-26 霍夫曼-拉罗奇有限公司 Ⅰ型和ⅱ型抗-cd20抗体的组合疗法
MX2010009647A (es) * 2008-03-25 2010-09-28 Roche Glycart Ag Uso de un anticuerpo anti-cd20 de tipo ii con citotoxicidad celular dependiente del anticuerpo aumentada en combinacion con ciclofosfamida, vincristina y doxorubicina para el tratamiento de linfoma no hodgkiniano.

Also Published As

Publication number Publication date
MY163544A (en) 2017-09-29
SI2268310T1 (sl) 2016-11-30
TWI500624B (zh) 2015-09-21
RU2010143454A (ru) 2012-05-10
US20100310581A1 (en) 2010-12-09
CR11687A (es) 2011-01-10
EP2268310B1 (en) 2016-07-20
JP2014101370A (ja) 2014-06-05
HRP20161301T1 (hr) 2016-11-18
RU2589704C2 (ru) 2016-07-10
JP2011515428A (ja) 2011-05-19
ES2592312T3 (es) 2016-11-29
ZA201006190B (en) 2018-11-28
JP5912142B2 (ja) 2016-04-27
PL2268310T3 (pl) 2017-08-31
AU2009228616B2 (en) 2014-07-24
KR20100121525A (ko) 2010-11-17
CY1117984T1 (el) 2017-05-17
JP2016121183A (ja) 2016-07-07
DK2268310T3 (en) 2016-08-15
AR072947A1 (es) 2010-10-06
BRPI0909227A2 (pt) 2015-12-01
HUE028828T2 (en) 2017-01-30
IL208018A0 (en) 2010-12-30
JP5547709B2 (ja) 2014-07-16
AU2009228616A1 (en) 2009-10-01
LT2268310T (lt) 2016-09-26
US20120301459A1 (en) 2012-11-29
NZ587284A (en) 2012-05-25
CN101983071A (zh) 2011-03-02
KR101280716B1 (ko) 2013-07-01
US20160000911A1 (en) 2016-01-07
CA2716884C (en) 2017-10-03
CA2716884A1 (en) 2009-10-01
CL2009000713A1 (es) 2010-04-09
JP6154039B2 (ja) 2017-06-28
IL208018A (en) 2017-12-31
US20140065134A1 (en) 2014-03-06
MA32140B1 (fr) 2011-03-01
TW200951141A (en) 2009-12-16
BRPI0909227B1 (pt) 2020-11-24
PT2268310T (pt) 2016-08-23
BRPI0909227B8 (pt) 2021-05-25
CN107198772A (zh) 2017-09-26
WO2009118142A1 (en) 2009-10-01
EP2268310A1 (en) 2011-01-05
US20110177067A1 (en) 2011-07-21
PE20091821A1 (es) 2009-11-25
US20090246197A1 (en) 2009-10-01
MX2010009647A (es) 2010-09-28

Similar Documents

Publication Publication Date Title
IL208018A0 (en) Use of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc) in combination with cyclophosphamide, vincristine and doxorubicine for treating non-hodgkin's lymphomas
IL254498B (en) Peptidomimetic macrocyclic composition for use in the treatment of diseases
ZA201002773B (en) Porcine dc-sign,icam-3 and lsectin and uses thereof
EP2377897A4 (en) ABSORBENT RESIN PARTICLES, PROCESS FOR PRODUCING THE SAME, AND ABSORPTION AGENT AND ABSORBENT ARTICLE COMPRISING SAME
EP1984175A4 (fr) Materiau multi-couches, procede de fabrication et utilisation comme electrode
EP2299957A4 (en) RECOVERY POUCHES IN ABSORBENT ARTICLES
IL200905A0 (en) Compounds and compositions comprising the same for use in treating hepatitis c
ZA200802274B (en) Absorbent article with improved garment-like character
EP2367665A4 (en) COMPOSITION AND PROCESS FOR TREATING WOOD-BASED MATERIAL AND WOOD-BASED MATERIAL PROCESSED WITH SAID COMPOSITION
EP2287267A4 (en) ANTITACHED AGENT COMPOSITION, PROCESS FOR PRODUCTION THEREOF, AND TREATMENT ARTICLE USING THE COMPOSITION
EP2177506A4 (en) POSITIVE RESIST COMPOSITION, PATTERN FORMATION METHOD USING THE COMPOSITION, AND COMPOUND USED IN THE COMPOSITION
EP2371904A4 (en) NEAR-INFRARED RAY-ABSORBING MATERIAL CONTAINING CYANINE COMPOUND AND CYANINE COMPOUND
HUE046349T2 (hu) Kompozíciók rákos sejtek kezelésére, és ezek szintézise
ZA200903771B (en) Carbamate compounds for use in treating depression
EP1948417A4 (en) METHOD OF DISPENSING ADDITIVE IN SPRAYING UNIT AND INJECTION UNIT
GB2435262B (en) Method, composition and articles
EP2085061A4 (en) METHOD OF MANUFACTURING ABSORBENT ARTICLE AND ABSORBENT ARTICLE
PL2110241T3 (pl) Materiał kompozytowy, zwłaszcza do elementów zapinających pieluchy, o wysokiej rozciągliwości i właściwościach półelastycznych
GB2450812B (en) Compound, ink, process and use
GB0708531D0 (en) Process, compound, ink and use
GB0612029D0 (en) Compound, ink, process and use
EP2007838A4 (en) MATERIAL ABSORBING INFRARED PROBES
GB0620089D0 (en) Process, composition and ink
ZA200902612B (en) Rubber composition for belt and rubber belt
GB0922009D0 (en) Compound, ink, process and use